Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | ELANE | P08246 | 1/20 | 0.63 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679558 | 1.00 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL27910275 | 0.89 | HSD17B10 (0.78) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL10520547 | 0.88 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNACYP2C19MAPT | |
| SCHEMBL459354 | 0.88 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL30395456 | 0.88 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11554371 | 0.87 | HSD17B10 (0.74) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL8548060 | 0.87 | HSD17B10 (0.74) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL903109 | 0.87 | HSD17B10 (1.00) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL14765558 | 0.85 | MAPT (0.77) | HSD17B10GPBAR1LMNACYP2C19ALDH1A1 | |
| SCHEMBL3451560 | 0.84 | TSHR (0.75) | GPBAR1LMNAALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1228332-C | Chemical synthesis method of 3-(2-chlorophenyl)-5-methyl-4-isoxazole formyl chloride | UNIV ZHEJIANG TECHNOLOGY (CN) | 2005-11-23 | — | — | CN | claimed |
| CN-1535960-A | Chemical synthesis method of 3-(2-chlorophenyl)-5-methyl-4-isoxazole formyl chloride | 浙江工业大学 | 2004-10-13 | — | — | CN | claimed |
| US-10450280-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450280-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3250565-B1 | TETRAZOLONES AS CARBOXYLIC ACID BIOISOSTERES | RIGEL PHARMACEUTICALS INC (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3250565-B1 | TETRAZOLONES AS CARBOXYLIC ACID BIOISOSTERES | RIGEL PHARMACEUTICALS INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180002297-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | MIDCAP FINANCIAL TRUST | 2018-01-04 | — | — | US | disclosed |
| US-20180002297-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | MIDCAP FINANCIAL TRUST | 2018-01-04 | — | — | US | disclosed |
| EP-3250565-A1 | TETRAZOLONES AS CARBOXYLIC ACID BIOISOSTERES | Rigel Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9701647-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701647-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4113940-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4113946-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-4066831-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4065623-A | O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4056521-A | PENICILLINS, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-11-01 | — | — | US | disclosed |
| US-4012383-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450280-B2 | Tetrazolones as a carboxylic acid bioisosteres | GLS, CYP11B2, GLS2 | HSD17B10 431/4885GPBAR1 86/4885LMNA 2953/4885 |
| US-20180002297-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | GLS, CYP11B2, GLS2 | HSD17B10 431/4885GPBAR1 86/4885LMNA 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.